Answers are grounded in this paper and cite their sources.
Ischemic stroke begins as an acute vascular and bioenergetic event, but the later course of tissue injury and recovery is shaped by neuroinflammation in which microglia play a central role. Emerging evidence indicates that lipid metabolism is an under-integrated layer of microglial biology after stroke. This review proposes a temporal immunometabolic switch framework: in the acute phase, lipid storage and metabolic adaptation may help microglia tolerate excess fatty acids and contain injury, whereas in the chronic phase, unresolved lipid accumulation, cholesterol overload, and oxidized lipid signaling drive foamy microglia, defective resolution, and persistent neuroinflammation. We synthesize evidence on microglial lipid droplets, cholesterol metabolic reprogramming, phospholipid imbalance, sphingosine-1-phosphate signaling, and ferroptosis-related lipid peroxidation. On this basis we outline stage-specific therapeutic opportunities: limiting lipid peroxidation and inflammatory lipid mediator amplification acutely, promoting pro-resolving lipid mediator pathways and effective phagocytosis in the subacute phase, and restoring cholesterol turnover and lipid disposal, exemplified by CYP46A1 activation, during chronic recovery. Finally, we critically appraise the evidence underlying the protective-versus-detrimental interpretation of lipid droplets, discuss safety considerations of lipid-directed interventions, and propose how lipidomics-guided stratification could match lipid-directed therapies to the dominant lipid program at each disease stage.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: